arrowTo report an adverse event

arrowFor any other medical emergency or R&D questions


Choose site

Rottapharm | Madaus
is now part of Meda AB

Rottapharm|Madaus, an italian success story

Passion for research and courage to take risks: these are the merits of Luigi Rovati, professor of pharmacology at the University of Pavia, who in 1961 decided to leave his academic career to create a small laboratory of independent research, Rotta Research Laboratorium. To this day, Rottapharm|Madaus has continued to grow and has become what is now, a Group located in over 90 countries worldwide   with more than 1800 employees.

A flexible, cutting-edge company constantly devoted to the frontline of health and prevention where it has achieved, as of today, many goals.


Research is our mission

Rottapharm|Madaus engages in research, development, manufacturing, global marketing and distribution of branded clinically proven consumer healthcare products (“Cx-Products”), reimbursed prescription (“Rx-reimbursed”) products and natural extracts. The strength and recognition of its brands is supported by a continued focus on research and development and extensive clinical validation demonstrating the effectiveness and safety of its Rx-reimbursed products and Cx-Products. Cx-Products are developed, promoted and marketed through the same business model as the Rx-reimbursed products and today they account for the majority of the Group’s business activities. This model represents a highly distinctive element of the Group that differentiates it from other Consumer Healthcare and Personal Care companies. As a result, the Company has a significant competitive advantage in marketing both Cx-Products and Rx-reimbursed products to health professionals.

This has been possible, in particular, due to a strong tradition in rigorous research and development activities (“R&D”) implemented by the Group since its foundation and initially focused, like other pharmaceutical companies, on the development of Rx-reimbursed products. The R&D activity has extended over time to include, through the application of similar techniques and methodologies, the development of Cx-Products. Recently, the two research activities have been divided, by separating those dedicated to innovative medicines, which have been conferred to Rottapharm Biotech.


A natural evolution: from debuting in personal care …

With the acquisition, in 1999, of the brands Saugella and Babygella , the Group entered the sector of personal care sold in pharmacies/Cx products. From then on, the same philosophy at the foundation of Rottapharm's pharmaceutical production has been applied to Cx products: constant investments in research, rigors in productive standards, natural and highly selected raw materials, cutting-edge technologies in the production plants. The same strategic choice was shown some years later (2005) with the acquisition of the Biochimici PSN, an Italian company specialized in pharmaceutical dermocosmesis..


… to the development of nutraceuticals

Worthy of note is Rottapharm|Madaus’s role in the field of nutraceuticals. With the launching of Estromineral, in 2001, the Group officially entered the market of nutraceuticals. Estromineral – a dietary supplement with Soy Isoflavones for the treatment of menopause symptomatology – shortly became a pharmacy top seller. Today, thanks to the constant investment in research and development and an aimed extension of the line (with Estromineral Serena in 2002, Estromineral FIT in 2004 and Estromineral Lipid in 2010), Estromineral is the product line for the natural treatment of menopause most sold in Italian pharmacies. In parallel, Rottapharm’s know how in cardiology and rheumatology has led to the launching of new nutraceutics: Armolipid (natural cardiovascular protection, followed by Armolipid Plus and, in 2011, by Armolipid Prev), Fortilase (a dietary supplement with bromeline, endowed with anti-inflammatory and anti-edemic properties) and Ritmonutra. In addition to these products, the historical dietary supplements for sun protection: Carovit line (that entered Rottapharm’s products portfolio after the acquisition of Biochimici PSN) for the systemic preparation of the skin to photo-exposure and Biomineral for systemic hair care.